EP Patent

EP4142769A4 — ACTRII PROTEINS AND THEIR USE IN THE TREATMENT OF POST-CAPILLARY PULMONARY HYPERTENSION

Assigned to Acceleron Pharma Inc · Expires 2024-05-15 · 2y expired

What this patent protects

Patent listed against Letairis.

Drugs covered by this patent

Letairis (AMBRISENTAN) · Gilead Sciences

Patent Metadata

Patent number: EP4142769A4
Jurisdiction: EP
Classification: —
Expires: 2024-05-15
Drug substance claim: No
Drug product claim: No
Assignee: Acceleron Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.